Correction: Allenex sells its holding in Pharmacolog

Allenex sells its holding in Pharmacolog i Uppsala AB to some of the other
owners in the company for sek 300.000
Correction: corrected time of publishing.

Pharmacolog is a company that
develop systems to control content and concentration in liquid drugs, used
mainly in chemotherapy for cancer treatment. Pharmacolog is still in an early
phase and the company presently has products in development and validation.
Allenex have been a part-owner in the company since it was founded early
2007.

Allenex have now agreed with some of the other owners in Pharmacolog to
sell its holding in Pharmacolog to them, at a price of sek 300.000. The Allenex
booked value of this holding is sek 0. This sale will therefor mean a
corresponding profit for Allenex during the second quarter of 2012.

”Through
the sale of our holding in Pharamacolog we continue the work to turn Allenex
into a company purely within the area of transplantation products and services,
says Allenex CEO Anders Karlsson. “In Pharmacolog there is an active owner-group
that will now take a larger responsibility in company development”.

Allenex
AB discloses the information provided herein pursuant to the Securities Markets
Act And/or the Financial Instruments Trading Act. The information was submitted
for publication on April 27, 2012, at 13:02 CET.

For more information please
contact:

Anders Karlsson, CEO Allenex AB, tel: +4670-918 0010, e-mail:
anders.karlsson@allenex.se

Allenex is a life science company that develops,
manufactures and markets products and services for safer transplantations.
Allenex is listed on NASDAQ OMX Stockholm Small Cap (ticker: ALNX). 54 persons
are employed in the Allenex group.